US audit finds gaps linking FDA technology investments to modernization goals
The Government Accountability Office says the FDA's IT strategy meets six of eight planning practices but needs clearer investment links and performance oversight.

The US Food and Drug Administration needs to improve how it connects major technology investments to its strategic objectives, according to a Government Accountability Office report released November 18, 2026.
The watchdog reviewed the agency's information technology modernization plans and found they fully addressed six of eight leading practices for strategic planning. The FDA had documented goals, performance measures and responsibilities, but had not fully explained how it would monitor important modernization challenges or connect individual investments and resources to those goals.
The agency is funding 17 major IT investments, according to GAO. Those systems support its work overseeing medical products and protecting public health. GAO's conclusions concern the documentation and management of technology programmes, not a finding that the FDA's medical-product safety decisions were invalid.
The review also examined five large investments in greater detail. It found that the agency had established performance metrics aligned with strategic objectives, but could not demonstrate that it used those metrics to manage and improve one of the five programmes. This gap limits assurance that performance information is informing decisions about the investment.
GAO issued three recommendations: document how the agency will track modernization challenges, explain how its investments and spending connect to strategic goals, and show how performance measures inform management of the relevant digital transformation investment. The Department of Health and Human Services agreed with all three and described planned implementation steps.
A separate November 20 healthcare policy review from Alston & Bird highlighted the same audit, noting the need for better tracking of challenges and stronger connections between resources and strategic goals. The findings provide a benchmark for subsequent oversight of the FDA's technology spending, but do not quantify financial waste or establish that the agency's modernization programme has failed.
Spotted an error? Request a correction · Our editorial principles · Contact the newsroom